Home / India / Skin Cancer Therapeutics Market 2019 Driving Force, manufacturers Profiles: Amgen, Bristol-Myers Squibb Company, Daiichi Sankyo Company, F. Hoffmann-La Roche, Merck & Co., Mylan N.V., Novartis AG, Sun Pharmaceutical Industry

Skin Cancer Therapeutics Market 2019 Driving Force, manufacturers Profiles: Amgen, Bristol-Myers Squibb Company, Daiichi Sankyo Company, F. Hoffmann-La Roche, Merck & Co., Mylan N.V., Novartis AG, Sun Pharmaceutical Industry



The world market for skin cancer therapeutics is expected to experience a CAGR of 10.4% in the forecast period. Certain factors that stimulate market growth include an increased incidence of skin cancer, extensive R&D pipelines and awareness of skin cancer.

Detailed sample copy of updated analysis @ marketprognosis.com/sample-request/19787
Note: "If this link does not work in Internet Explorer, try copying it in other browsers".

Skin cancer is the most common form of cancer. Although most types of skin cancer are prevented, the incidence is increasing. People can recognize changes in their skin during the early stages of the disease. The risk factors are sunlight, sun lamps and tanning beds, certain medical conditions or medicines. The UV radiation changes the genetic material (DNA) in cells and is therefore the main cause of skin cancer. According to the American Cancer Society, sun exposure is the most preventable risk factor for all skin cancers. According to the National Cancer Institute, the number of new cases of melanoma among American adults has tripled since the 1970s, from 7.9 per 100,000 people in 1975 to 25.2 per 100,000 in 2014. The number of new melanoma cases in both men and women has increased by 1.7% and 1.4% per year, respectively, according to Federal Center for Disease Control and Prevention (CDC) data. The increasing prevalence of skin cancer therefore increases the growth of the market studied.

Competitive landscape
The world market for skin cancer therapeutics is very competitive and consists of a number of important players. Companies such as Amgen, Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Mylan NV, Novartis AG, Sun Pharmaceutical Industries Ltd., and Varian Medical Systems, Inc., among others, have significant market share in the skin cancer drug market.

Request a discount on this report @ marketprognosis.com/discount-request/19787
Note: "If this link does not work in Internet Explorer, try copying it in other browsers".

A common side effect of radiation therapy is skin irritation in the area of ​​the body being treated. The skin reaction can range from mild redness and dryness (similar to sunburn) to severe peeling (desquamation) of the skin in some patients. Most skin reactions to radiation therapy disappear a few weeks after the treatment is completed. In some cases the treated skin stays slightly darker than before and may be even more sensitive to sun exposure. About two to three weeks after the first radiation treatment, redness is noticed and irritation resembles a sunburn. The skin can be itchy, dry, red or sore. There are also long-term side effects, such as changes in skin color, lung problems and others, that act as major constraints on the growth of the market studied.

Scope of the report
Ultraviolet radiation is a primary carcinogen that results in UV-induced mutations, loss of activity in tumor suppressor genes and the overexpression of oncogenes in keratinocytes, thereby enhancing the development of skin cancer. The market for skin cancer therapeutics consists of various therapies related to skin cancer.

Important market trends
Non-melanoma is expected to hold a significant market share in the type of disease
According to the ASCO (American Society of Clinical Oncology), it is estimated that more than 3 million people in the United States are diagnosed with non-melanoma cancer each year. Basal cell carcinoma is much more common than squamous cell carcinoma. About 80% of skin cancers without melanoma are basal cell carcinoma. Similarly, the CCS (Canadian Cancer Society) states that non-melanoma skin cancer is the most common cancer among Canadians. It makes up at least 40% of all new cancer cases in Canada.

North America dominates the market and is expected to do the same in the forecast period
It is expected that North America will dominate the market during the forecast period. According to the American Academy of Dermatology, skin cancer is the most common cancer in the United States. Most cases of melanoma, the deadliest form of skin cancer, are caused by exposure to ultraviolet (UV) light. An estimated 9,500 people in the United States are diagnosed with skin cancer every day. So the increasing incidence of skin cancer in the region is an important factor that stimulates the growth of the market investigated. In addition, recent advances in skin cancer treatment, including photodynamic therapy (PDT), have been widely used in the treatment of non-melanoma skin cancer, thereby increasing the growth of the market studied during the forecasting period.

Ask @ marketprognosis.com/enquiry/19787 before buying
Note: "If this link does not work in Internet Explorer, try copying it in other browsers".

About market forecast
We at Market Prognosis believe in providing a crystal clear picture of market dynamics for achieving success in today's complex and competitive market through our quantitative and qualitative research methods.
We help our customers identify the best market insights and analyzes that are needed for their business so that they can make strategic and intelligent decisions.
We believe in providing useful insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane – 421501
India.
Contact number: +1 973 241 5193
Email: sales@marketprognosis.com

This release has been published on openPR.


Source link